Why Prognos?

Prognos is an innovative healthcare AI company that’s striving to improve health by tracking and predicting disease earlier in partnership with Life Sciences brands, payers, and clinical diagnostics organizations.

Prognos’ innovations enhance the value of laboratory results and clinical diagnostic data through advanced analytics and artificial intelligence techniques.

The Prognos Registry of 5 billion clinical records for 100 million patients in over 30 disease areas enables earlier identification of patients who can benefit from enhanced treatment decision-making, risk management, and quality improvement under the HEDIS guidelines. During its research and development phase as Medivo, Prognos invested in innovations exploring the potential of clinical diagnostic assets and is now realizing the full value of those assets through AI and HIPAA-compliant advanced analytics with over 500 proprietary and learning clinical algorithms.

Payer organizations can now take advantage of Prognos’ solutions to engage with providers earlier in the patient treatment process, improving the overall quality of care. By connecting payers directly with the lab, Prognos has the added benefit of accessing clinical diagnostic data on the payer’s behalf, enhancing the resulting insights. Identifying and reaching at-risk patients earlier can help plans to reduce avoidable care costs, especially for patients with chronic conditions and comorbidities.

Life Sciences organizations can leverage Prognos products to determine specific and complex patient journeys and help brands dependent on biomarkers commercialize highly targeted patient selection strategies for the treating physicians. Prognos’ “Trigger” solution identifies newly diagnosed patients and provides weekly alerts to help brands educate providers on therapy options before treatment decisions are made. Prognos currently works with 17 Life Sciences organizations.

Diagnostics organizations can partner with Prognos to leverage their lab data and clinical and technology expertise with Prognos analytic solutions. Such partnerships further the ability of lab data to inform physicians and increase the likelihood that patients can access the treatments that will improve their care outcomes. Current diagnostic collaborators include Quest Diagnostics and Laboratory Corporation of America Holdings (LabCorp). The Prognos Registry includes data from hundreds of labs and diagnostics companies.

Market Opportunity

Prognos generates revenue through targeting and analytics programs and clinical services. Based on current monetization strategies, the addressable healthcare analytics market for Prognos’ products is estimated to reach $10.8 billion.

(Visited 662 times, 1 visits today)

Company Milestones

  • Medivo acquires Physicians Wellness Network (PWN)
  • Medivo launches free mobile and web-based app for hereditary angiodema
  • Medivo acquires mobile health startup WellApps
  • Medivo acquires diabetes management app OnTrack
  • Medivo partners with NeoGenomics Laboratories to expand Medivo's Lab Value Exchange (LVX) database
  • Medivo forms laboratory data liscensing agreement with Quest Diagnostics (NYSE:DGX)
  • Medivo launches CareInsights Dx analytics solutions to help payers better manage risk and improve quality
  • Medivo changes its name to Prognos

Eradicating disease by driving decisions earlier in healthcare.